Metabolic · ~3 min read
Mazdutide: What It Is, How It Works & What the Research Shows
Overview
Dual GLP-1 / glucagon receptor agonist approved in China in 2025 (Innovent) for obesity, with research in type 2 diabetes and hepatic fat reduction. It is not FDA-approved.
How it works
Dual GLP-1 / glucagon receptor agonist approved in China in 2025 (Innovent) for obesity, with research in type 2 diabetes and hepatic fat reduction. It is not FDA-approved.
Adamantane & the blood–brain barrier
Chemically attaching an adamantane group to a peptide can increase its lipid (fat) solubility. Researchers hypothesize that this modification may help certain compounds cross the tightly regulated blood–brain barrier. The effect depends on the specific modified molecule; greater lipid solubility alone does not establish brain delivery or clinical benefit. This does not apply automatically to the unmodified peptide and is not a reconstitution additive.
What the research shows
- Significant weight loss
- Reduced hepatic fat
- Improved glycemic control
Typical protocol
Community-reported range (unverified): 3–9 mg/week SC
Community-reported range (unverified); not a clinically verified schedule.
The dossier calculator is a pure math tool, not compound-specific preparation guidance.
Sources
Not currently carried by Orbitrex.
Compare research suppliers →